Atopic Dermatitis
Conference Coverage
Children With Severe Atopic Dermatitis Catch Up on Growth With Dupilumab
Children at the lower percentiles of height receiving prompt treatment with dupilumab “were able to rapidly move through the centiles over the 16...
Latest News
Nemolizumab Benefits for Atopic Dermatitis Maintained in Long-Term Follow-Up Study
Nemolizumab was associated with “ongoing clinically meaningful improvements in itch, skin lesions, and sleep disturbance,” reported Dr. Diamant...
Latest News
Study Finds No Increased MACE Risk for JAK Inhibitors in Patients With Atopic Dermatitis
The analysis looked at treatment with the upadacitinib and abrocitinib (Cibinqo), both approved for treating AD in...
Latest News
Topical JAK Inhibitor Effective for Hand Eczema, Two Studies Suggest
Delgocitinib cream, currently under FDA review for chronic hand eczema, was recently approved in Europe for treating adults with moderate to...
Cosmeceutical Critique
Sea Buckthorn
Used as a health supplement and consumed in the diet throughout the world, sea buckthorn berries, seeds, and leaves have been used in traditional...
Latest News
Gardasil 9 at 10 Years: Vaccine Protects Against Multiple Cancers
The WHO has predicted that the 21st century may be the last to experience HPV-associated cancers, currently responsible for more than...
Conference Coverage
Parent Perceptions Drive Diet Changes for Children With Atopic Dermatitis
The current study highlights the need for more awareness of the limited impact of dietary modifications on atopic dermatitis in the absence of...
Latest News
Atopic Dermatitis: Upadacitinib Effectiveness Maintained Through 76 weeks Among Adolescents
Among those who continued treatment on upadacitinib, 15 mg and 30 mg, EASI-75 response rates were maintained or improved through week 76 in three...
Case Letter
Phenytoin-Induced DRESS Syndrome: Clinical and Laboratory Characteristics
To the Editor:
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome—a severe cutaneous adverse drug reaction—is...
Latest News
Over 3 Years, Atopic Dermatitis Well-Controlled with Lebrikizumab
“Over the whole follow-up, 90% had no need for topical corticosteroids or any other rescue therapy,” reported Diamant Thaçi, MD, PhD.
Latest News
Different Biomarker Profiles Identified in Study of Late Dupilumab Responders
A discovery that could lead to personalizing therapies, the data identified “distinct systemic biomarker profiles,” Ester Del Duca, MD, said.